Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

• Published in: British journal of cancer 2018-04, Vol.118 (8), p.1084-1088
• Main Authors: Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M., Charnley, R. M., Anthoney, A., Lerch, M. M., Mayerle, J., Oláh, A., Büchler, M. W., Greenhalf, W.
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; 631/67/1059/99; 692/53/2422; 692/53/2423; Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - surgery; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor - metabolism; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy; Chemotherapy, Adjuvant; Clinical trials; DCMP Deaminase - metabolism; Disease-Free Survival; Drug Resistance; Epidemiology; Folinic acid; Gemcitabine; Humans; Immunohistochemistry; Molecular Medicine; Oncology; Pancreatectomy; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - surgery; Patients; Prognosis; Randomized Controlled Trials as Topic; Reductase; Ribonucleoside Diphosphate Reductase; Tissue Array Analysis; Tumor Suppressor Proteins - metabolism; Tumors
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/s41416-018-0005-1

Background Deoxycytidylate deaminase (DCTD) and ribonucleotide reductase subunit M1 (RRM1) are potential prognostic and predictive biomarkers for pyrimidine-based chemotherapy in pancreatic adenocarcinoma. Methods Immunohistochemical staining of DCTD and RRM1 was performed on tissue microarrays representing tumour samples from 303 patients in European Study Group for Pancreatic Cancer (ESPAC)-randomised adjuvant trials following pancreatic resection, 272 of whom had received gemcitabine or 5-fluorouracil with folinic acid in ESPAC-3(v2), and 31 patients from the combined ESPAC-3(v1) and ESPAC-1 post-operative pure observational groups. Results Neither log-rank testing on dichotomised strata or Cox proportional hazard regression showed any relationship of DCTD or RRM1 expression levels to survival overall or by treatment group. Conclusions Expression of either DCTD or RRM1 was not prognostic or predictive in patients with pancreatic adenocarcinoma who had had post-operative chemotherapy with either gemcitabine or 5-fluorouracil with folinic acid.